# Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

> **NCT01032915** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 125 (actual)

## Conditions studied

- Non-infectious Uveitis

## Interventions

- **BIOLOGICAL:** AIN457
- **BIOLOGICAL:** AIN457
- **BIOLOGICAL:** AIN457
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01032915
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 125 (ACTUAL)
- **Why stopped:** Results of a planned interim analysis did not show significant effects for any of the 3 AIN dose regimens versus placebo on any primary or secondary endpoint
- **Last updated:** 2015-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01032915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01032915, "Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01032915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*